Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04910789

Transhiatal/Transabdominal Approach Compare With Thoracoabdominal Approach for Siewert II Adenocarcinoma of Esophagogastric Junction

Adenocarcinoma of Esophagogastric Junction Clinical Trial

Official title:
A Prospective, Multicenter, Randomized, Controlled Study Comparing Surgical Efficacy Between Transhiatal/Transabdominal and Thoracoabdominal Approach for Patients With Siewert II Adenocarcinoma of Esophagogastric Junction

Clinical Trial Summary

To compare transhiatal / transabdominal approach with thoracoabdominal approach for Siewert II adenocarcinoma of esophagogastric junction

Clinical Trial Description

Objective: To compare the safety and clinical efficacy between transhiatal/transabdominal and thoracoabdominal approach for Siewert Ⅱ adenocarcinoma of esophagogastric junction. Methods: A prospective, multi-center, randomized, controlled study will be performed. Patients who meet the eligibility criteria will be registered in the study and undergo radical surgery via transhiatal/transabdominal or thoracoabdominal approach. The data of preoperative, intraoperative, postoperative and follow-up will be recorded and analyzed. The primary endpoints :3-year disease-free survival. The secondary endpoints:(1) Surgery and oncology indicators ;(2) The incidences of postoperative complications and mortality. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04910789
Study type Interventional
Source Chinese PLA General Hospital
Contact Xinxin Wang, Dr
Phone +8613811858199
Email 301wxx@sina.com
Status Recruiting
Phase N/A
Start date December 11, 2019
Completion date December 31, 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05829213 - A Modified Esophagogastric Reconstruction Method After Laparoscopic Proximal Gastrectomy N/A
Recruiting NCT05729646 - Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma Phase 2
Not yet recruiting NCT04891900 - TQB2450 (PD-L1 Inhibitor) Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma N/A
Active, not recruiting NCT01095120 - Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer Phase 2
Not yet recruiting NCT05970627 - Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma Phase 2
Recruiting NCT03734913 - A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors Phase 1
Not yet recruiting NCT05505461 - Neoadjuvant Immunotherapy and Chemoradiotherapy for Locally Advanced Esophagogastric Junction Adenocarcinoma Phase 2
Recruiting NCT06300879 - A Prospective Study on Esophagogastrostomy by an Innovative Surgical Technique N/A
Recruiting NCT05715931 - Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma Phase 2
Not yet recruiting NCT06222944 - Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA Phase 2
Active, not recruiting NCT03302403 - Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors N/A
Recruiting NCT05872685 - Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05) Phase 2
Recruiting NCT04813523 - Pembrolizumab Plus Neoadjuvant Chemotherapy for Locally Advanced EGJ Adenocarcinoma Phase 2